** Medical device maker Stryker SYK.N rise 1.2% to $395
** Brokerage Citi Research resumes coverage on SYK with "buy" rating; sets PT at $450, 15.3% upside to the stock's last close
** Brokerage says SYK has built a diversified business through multiple buys such as the $4.9 billion Inari medical acquisition, which added Inari's ClotTriever and FlowTriever devices that treat venous thromboembolism (VTE)
** VTE — a disease where blood clots form in veins — is estimated to impact more than 900,000 patients annually in the U.S., brokerage says
** SYK estimates the value of the VTE market at $15 billion globally, including $6 billion in the U.S.
** Citi calls the Inari acquisition "another step in SYK evolution"
** Stock has risen 10.7% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。